Evidence map›Paper›PMID 38557819›Full record

ArticlePloS one2024

CAF-associated genes putatively representing distinct prognosis by in silico landscape of stromal components of colon cancer.

Kota Okuno, Kyonosuke Ikemura, Riku Okamoto, Keiko Oki, Akiko Watanabe, Yu Kuroda, Mikiko Kidachi, Shiori Fujino, Yusuke Nie, Tadashi Higuchi and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Kota OkunoDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.ORCID 0000-0002-0273-0846
Kyonosuke IkemuraDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Riku OkamotoDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Keiko OkiDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Akiko WatanabeDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Yu KurodaDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Mikiko KidachiDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Shiori FujinoDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.
Yusuke NieDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.ORCID 0000-0002-0755-9689
Tadashi HiguchiDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Motohiro ChumanDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Marie WashioDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Mikiko SakurayaDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Masahiro NiiharaDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Koshi KumagaiDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Takafumi SangaiDepartment of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Yusuke KumamotoDepartment of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Takeshi NaitohDepartment of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Naoki HikiDepartment of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Keishi YamashitaDivision of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.ORCID 0000-0002-8492-0300
Kitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive understanding prognostic relevance of distinct tumor microenvironment (TME) remained elusive in colon cancer. In this study, we performed in silico analysis of the stromal components of primary colon cancer, with a focus on the markers of cancer-associated fibroblasts (CAF) and tumor-associated endothelia (TAE), as well as immunological infiltrates like tumor-associated myeloid cells (TAMC) and cytotoxic T lymphocytes (CTL). The relevant CAF-associated genes (CAFG)(representing R index = 0.9 or beyond with SPARC) were selected based on stroma specificity (cancer stroma/epithelia, cS/E = 10 or beyond) and expression amounts, which were largely exhibited negative prognostic impacts. CAFG were partially shared with TAE-associated genes (TAEG)(PLAT, ANXA1, and PTRF) and TAMC-associated genes (TAMCG)(NNMT), but not with CTL-associated genes (CTLG). Intriguingly, CAFG were prognostically subclassified in order of fibrosis (representing COL5A2, COL5A1, and COL12A1) followed by exclusive TAEG and TAMCG. Prognosis was independently stratified by CD8A, a CTL marker, in the context of low expression of the strongest negative prognostic CAFG, COL8A1. CTLG were comprehensively identified as IFNG, B2M, and TLR4, in the group of low S/E, representing good prognosis. Our current in silico analysis of the micro-dissected stromal gene signatures with prognostic relevance clarified comprehensive understanding of clinical features of the TME and provides deep insights of the landscape.

Indexed as

Cancer-Associated FibroblastsColonic NeoplasmsHumansPrognosisTumor Microenvironment

Identifiers

PMID38557819
PMCPMC10984474
OpenAlexW4393373918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.